NeurAxis (NRXS) said Monday it received a new 510(k) clearance from the US Food and Drug Administration for its IB-Stim nerve stimulator for functional abdominal pain relief, expanding its indication for use in people between 8 and 21 years of age from a previous indication for 11- to 18-year olds.
IB-Stim is a non-surgical device that sends "gentle" electrical impulses into cranial nerve bundles in the ear, the medical technology company said.
Price: 2.26, Change: -0.33, Percent Change: -12.74
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments